CGRP Antibodies as Prophylaxis in Migraine

Lars Edvinsson

doi:10.1016/j.cell.2018.11.049

CGRP Antibodies as Prophylaxis in Migraine

Lars Edvinsson

42 Citations (Scopus)

Abstract

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

Original language	English
Journal	Cell
Volume	175
Issue number	7
Pages (from-to)	1719
ISSN	0092-8674
DOIs	https://doi.org/10.1016/j.cell.2018.11.049
Publication status	Published - 2018
Externally published	Yes

Access to Document

10.1016/j.cell.2018.11.049

Cite this

@article{175b99bf5d6c49b99df68b35ec4c6bfe,

title = "CGRP Antibodies as Prophylaxis in Migraine",

abstract = "Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.",

author = "Lars Edvinsson",

note = "Copyright {\textcopyright} 2018. Published by Elsevier Inc.",

year = "2018",

doi = "10.1016/j.cell.2018.11.049",

language = "English",

volume = "175",

pages = "1719",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier BV",

number = "7",

}

TY - JOUR

T1 - CGRP Antibodies as Prophylaxis in Migraine

AU - Edvinsson, Lars

PY - 2018

Y1 - 2018

N2 - Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

AB - Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

UR - https://www.scopus.com/pages/publications/85058023044

U2 - 10.1016/j.cell.2018.11.049

DO - 10.1016/j.cell.2018.11.049

M3 - Journal article

C2 - 30550780

SN - 0092-8674

VL - 175

SP - 1719

JO - Cell

JF - Cell

IS - 7

ER -

CGRP Antibodies as Prophylaxis in Migraine

Abstract

Access to Document

Other files and links

Fingerprint

Cite this